Insilico Medicine

Insilico

Insilico Medicine’s AI-Discovered Drug to Treat Lung Disease Enters Human Trial

PRESS RELEASE — Insilico Medicine, an end-to-end artificial intelligence (AI)-driven drug discovery company, announced that the first healthy volunteer has been dosed in a first-in-human microdose trial of ISM001-055. ISM001-055 is a potentially first-in-class small molecule inhibitor of a novel biological target discovered by Pharma.AI, Insilico Medicine’s end-to-end AI-powered drug discovery platform. It is being developed …

Insilico Medicine’s AI-Discovered Drug to Treat Lung Disease Enters Human Trial Read More »

Insilico

Insilico Medicine Raises $255 Million in Series C Financing Led by Warburg Pincus

 Insilico Medicine, a global leader in end-to-end artificial intelligence for target discovery, small molecule chemistry, and clinical development, announced that it has closed a $255 million Series C financing led by Warburg Pincus. The financing was also participated by current investors including Qiming Venture Partners, Pavilion Capital, Eight Roads Ventures, Lilly Asia Ventures, Sinovation Ventures, …

Insilico Medicine Raises $255 Million in Series C Financing Led by Warburg Pincus Read More »